Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
Bullboard Posts
User Avatar Image
(26)
•••
Comment by colimaon Jul 10, 2018 10:12pm
119 Views
Post# 28297229

RE:RE:RE:RE:RE:throwing out #'s

RE:RE:RE:RE:RE:throwing out #'sfirst US customer for the ground-breaking VMS Plus machine. And that buyer is no less than the MD Anderson Cancer Center in Texas - the number-one ranked cancer centre in the US. It comprises a network of hospitals who see an eye-watering 1.5mln patients per year and perform almost 600,000 imaging studies. News of this first sale comes after last month, the emerging medtech firm received the all-important FDA approval to sell the device with the four-chamber heart analysis system in the USA. Doctors at MD Anderson will be using the VMS+ to monitor cardiac function in cancer patients since it is well known that chemotherapy agents are cardiotoxic and lead to significant patients acquiring heart dysfunction. They are to start using it immediately clinically.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities